# Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA

> **NCT07070466** · PHASE2 · RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Stomach Cancer Stage IV
- Esophagus Cancer
- Stomach Cancer

## Interventions

- **DRUG:** Ivonescimab
- **DRUG:** 5-Fluorouracil
- **DRUG:** Oxaliplatin
- **DRUG:** Leucovorin

## Key facts

- **NCT ID:** NCT07070466
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-10
- **Primary completion:** 2026-12-01
- **Final completion:** 2028-09-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07070466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07070466, "Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07070466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*